Barinthus Biotherapeutics (STU:2AB) Insider Ownership: 0.00 % (As of Jul. 09, 2026)


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.54
GF Value €0.98
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Insider Ownership?

Barinthus Biotherapeutics STU:2AB -2.73% 14 Insider Ownership is 0.00 % as of Jul. 09, 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.98. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Barinthus Biotherapeutics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Barinthus Biotherapeutics's Institutional Ownership is 0.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Barinthus Biotherapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Barinthus Biotherapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Insider Ownership Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Barinthus Biotherapeutics (STU:2AB) has a Insider Ownership of 0.00 % as of Jul. 09, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Insider Ownership too high?
Barinthus Biotherapeutics' current Insider Ownership is 0.00 %. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Insider Ownership compare to VTGN and PSTV?
Barinthus Biotherapeutics' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Insider Ownership of 0.00 %. The stock's GF Value™ is €0.98, compared to a current price of €0.54 — trading 45.4% below its estimated fair value. The current Insider Ownership is 0.00 %. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Insider Ownership is 0.00 % as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.54 is trading 45.4% below its estimated GF Value™ of €0.98.

Key valuation signals for STU:2AB:

  • Insider Ownership: 0.00 %
  • GF Value™: €0.98 vs. price of €0.54 (45.4% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.54
Price
€0.98
GF Value